Small study explores how genetics affect diabetes drug response

NCT ID NCT04323189

Ongoing Knowledge-focused Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study looks at how the diabetes drug sitagliptin (Januvia) affects people who naturally have lower levels of a protein called DPP4 due to their genes. Researchers will compare 20 adults with and without this genetic trait to see how sitagliptin changes blood sugar and DPP4 activity after a meal. The goal is to better understand how genetics influence drug response, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sitagliptin (Januvia)
What this could lead to: If successful, this could help explain why some people respond differently to sitagliptin, potentially leading to more personalized diabetes treatment.
What could go wrong: This is a very small pilot study with only 20 participants, so results may not apply to the general population. It is designed to gather information, not to prove a new treatment works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENETICS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure hereditary disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENETICS DISEASE HEART FAILURE TYPE2 DIABETES

Contacts and locations

Locations

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.